Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/2019 the French National Agency for Medicines...

Full description

Bibliographic Details
Main Authors: E. Gaudre Wattinne, L. Mekaoui, M. Rothärmel, M.A. Codet, S. Bouju
Format: Article
Language:English
Published: Cambridge University Press 2021-04-01
Series:European Psychiatry
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S0924933821018344/type/journal_article